Ketamine Hydrochloride Injection
NDC Package 43066-177-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Ketamine Hydrochloride injection is indicated:•as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.•for the induction of anesthesia prior to the administration of other general anesthetic agents.•as a supplement to other anesthetic agents. This formulation utilizes a injection delivery system. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 43066-177 and is authorized under FDA application ANDA219684.

Identification & Billing

NDC Package Code
43066-177-05
Package Description
5 CARTON in 1 CARTON / 1 SYRINGE, PLASTIC in 1 CARTON (43066-177-01) / 10 mL in 1 SYRINGE, PLASTIC
Product Code
11-Digit Billing Format
43066017705
RxNorm Crosswalk
  • RxCUI: 2723913 - ketamine 100 MG in 10 ML Prefilled Syringe
  • RxCUI: 2723913 - 10 ML ketamine 10 MG/ML Prefilled Syringe
  • RxCUI: 2723913 - ketamine 100 MG (as ketamine hydrochloride 115.3 MG) per 10 ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Ketamine Hydrochloride
Non-Proprietary Name
Ketamine Hydrochloride
Substance Name
Ketamine Hydrochloride
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
Ketamine hydrochloride injection is indicated:•as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.•for the induction of anesthesia prior to the administration of other general anesthetic agents.•as a supplement to other anesthetic agents.
DEA Schedule
Schedule III (CIII) Substances

Regulatory & Marketing

Labeler Name
Baxter Healthcare Corporation
Product Type
Human Prescription Drug
FDA Application #
ANDA219684
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-17-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 43066-177-05 identifies a specific commercial package of 5 carton in 1 carton / 1 syringe, plastic in 1 carton (43066-177-01) / 10 ml in 1 syringe, plastic of Ketamine Hydrochloride, a human prescription drug labeled by Baxter Healthcare Corporation. This injection is formulated for intramuscular; intravenous use and contains ketamine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Corporation on September 17, 2025. The current certification is valid through December 31, 2026.

How is this Baxter Healthcare Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 43066017705. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
43066-177-05
11-Digit CMS (5-4-2)
43066-0177-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.